High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study

被引：14
|
作者：
Guida, Michele [1 ]
Cramarossa, Antonio [2 ]
Fistola, Ettore [1 ]
Porcelli, Mariangela [1 ]
Giudice, Giuseppe [3 ]
Lubello, Katia [1 ]
Colucci, Giuseppe [1 ]
机构：
[1] Natl Canc Inst, Dept Med Oncol, Bari, Italy
[2] Natl Canc Inst, Dept Radiol, Bari, Italy
[3] Natl Canc Inst, Dept Plast & Reconstruct Surg, Bari, Italy
来源：
JOURNAL OF TRANSLATIONAL MEDICINE | 2010年 / 8卷
关键词：
DISSEMINATED MALIGNANT-MELANOMA; PHASE-III; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; GLIOBLASTOMA PATIENTS; CEREBRAL METASTASES; ALKYLATING-AGENTS; ONCOLOGY-GROUP; DACARBAZINE; MGMT; CHEMOTHERAPY;
D O I：
10.1186/1479-5876-8-115
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
[No abstract available]
引用
收藏
页数：8
相关论文
共 38 条
  • [31] Phase II study of the anti-ganglioside GD3 mouse/human chimeric antibody KW2871 combined with high dose interferon-a2b in patients with metastatic melanoma.
    Moschos, Stergios J.
    Tarhini, Ahmad A.
    Gajewski, Thomas
    Scott, Andrew Mark
    Lin, Yan
    Shipe-Spotloe, Janice
    Deblasio, Weiping Xu
    Sander, Cindy
    Matijevich, Karen
    Smyth, Fiona Elizabeth
    Liu, Zhanqi
    Hoffman, Eric W.
    Venhaus, Ralph Rudolph
    Pan, Linda S.
    Sinhan Tran
    Fiore, James
    Kirkwood, John M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] Safety and clinical activity of TTI-621 in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma: Results from the low-dose expansion cohort
    Movva, Sujana
    Druta, Mihaela
    Davis, Lara E.
    Monga, Varun
    Milhem, Mohammed M.
    Bailey, Howard Harry
    Chugh, Rashmi
    Bruns, Ingmar
    Allgood, Victoria E.
    Chawla, Sant P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] Phase I/II dose escalation and expansion cohort safety and efficacy study of image guided intratumoral CD40 agonistic monoclonal antibody APX005M in combination with systemic pembrolizumab for treatment naive metastatic melanoma.
    Johnson, Daniel H.
    Bentebibel, Salah E.
    Lecagoonporn, Srisuda
    Bernatchez, Chantale
    Haymaker, Cara L.
    Murthy, Ravi
    Tam, Alda
    Yee, Cassian
    Amaria, Rodabe Navroze
    Patel, Sapna Pradyuman
    Tawbi, Hussein Abdul-Hassan
    Glitza, Isabella Claudia
    Davies, Michael A.
    Hwu, Wen-Jen
    Hwu, Patrick
    Overwijk, Willem W.
    Diab, Adi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [34] Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha
    Groenewegen, G
    Bloem, A
    de Gast, GC
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2002, 51 (11-12) : 630 - 636
  • [35] Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha
    Gerard Groenewegen
    Andries Bloem
    Gijsbert C. de Gast
    [J]. Cancer Immunology, Immunotherapy, 2002, 51 : 630 - 636
  • [36] Feasibility of utilizing ultra-low-dose contrast medium for pancreatic artery depiction using the combination of advanced virtual monoenergetic imaging and high-concentration contrast medium: an intra-patient study
    Li, Juan
    Wang, Yu-hong
    Zheng, Fu-ling
    Chen, Xin-yue
    Lin, Yun
    Zhu, Cai-rong
    Wu, Yi-fan
    Xu, Qiang
    Jin, Zheng-yu
    Xue, Hua-dan
    [J]. INSIGHTS INTO IMAGING, 2021, 12 (01)
  • [37] Feasibility of utilizing ultra-low-dose contrast medium for pancreatic artery depiction using the combination of advanced virtual monoenergetic imaging and high-concentration contrast medium: an intra-patient study
    Juan Li
    Yu-hong Wang
    Fu-ling Zheng
    Xin-yue Chen
    Yun Lin
    Cai-rong Zhu
    Yi-fan Wu
    Qiang Xu
    Zheng-yu Jin
    Hua-dan Xue
    [J]. Insights into Imaging, 12
  • [38] Sequential high-dose idarubicin (IDA) and alkylating agents with blood cell support (BCS) following epirubicin-paclitaxel-gemcitabine (GET) combination in metastatic breast cancer (MBC): A phase I/II study with pharmacokinetic profile analysis.
    Bengala, C
    Danesi, R
    Pazzagli, I
    Donati, S
    Favre, C
    Menconi, MC
    Innocenti, F
    Guarneri, V
    Del Tacca, M
    Conte, PF
    Cazzola, M
    [J]. BLOOD, 1999, 94 (10) : 354B - 354B
1234